secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001628280-24-007964
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Q4 rev $32.7M (-26% YoY); guides 2024 rev $95.5-100M ex-freezer; adj EBITDA positive
--------------------------------------------------------------------------------

- Q4 GAAP net loss $13.4M ($0.30 loss/share) vs $49.2M loss ($1.15) in Q4 2022.
- Cell Processing platform Q4 rev $14.8M, down 27% YoY but up 11% sequentially.
- Freezer divestiture underway; expects sale by end of Q1 2024.
- 2024 revenue guidance $95.5-100.0M (ex-freezer); expects full-year positive adjusted EBITDA.
- Biopreservation media embedded in 14 approved CGT therapies as of Feb 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828024007964/0001628280-24-007964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828024007964/blfs-20240229.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-007964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer